Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors.

Saved in:
Bibliographic Details
Title: Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors.
Authors: Penny CL; Duke University School of Medicine, Durham, NC, USA., Quow K; Department of Dermatology., Rundle CW; Department of Dermatology., Al-Rohil RN; Department of Dermatology.; Department of Pathology, Duke University Medical Center, Durham, NC, USA., Cardones AR; Department of Dermatology., Kheterpal MK; Department of Dermatology., Fresco AI; Department of Dermatology.
Source: The British journal of dermatology [Br J Dermatol] 2022 Aug; Vol. 187 (2), pp. 275-276. Date of Electronic Publication: 2022 May 24.
Publication Type: Letter; Comment
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1365-2133
DOI:10.1111/bjd.21239